On September 1, 2021 Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics for the treatment of cancer and autoimmune diseases, reported that the Company’s executive management team will participate in the Morgan Stanley 19th Annual Global Healthcare Conference on September 9-13, 2021, and the H.C. Wainwright 23rd Annual Global Investment Conference on September 14, 2021 (Press release, Rubius Therapeutics, SEP 1, 2021, View Source [SID1234587086]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Pablo J. Cagnoni, M.D., president and chief executive officer will provide a corporate update through a fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on September 10, 2021, at 9:30 a.m. EDT. A live audio webcast will be available within the Investors & Media section of the Rubius Therapeutics website. An archived replay will be accessible for 90 days following the event.

Members of the executive management team will host meetings with investors at the H.C. Wainwright 23rd Annual Global Investment Conference on September 14, 2021.